Compare Merck & Co., Inc. (MRK) vs Xpeng Inc - ADR (XPEV) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Merck & Co., Inc. vs Xpeng Inc - ADR — how do they compare? Merck & Co., Inc. trades at $146.05 (market cap $351.28B), while Xpeng Inc - ADR trades at $9.91 (market cap $9.16B). The key difference: Merck & Co., Inc. is far larger — about 38.3× Xpeng Inc - ADR's market cap, and Merck & Co., Inc. pays a 2.39% dividend while Xpeng Inc - ADR pays none. Which is the better fit depends on your goals — on Pluang, investors hold Merck & Co., Inc. for 98 Days and Xpeng Inc - ADR for 80 Days on average.
| MRK | XPEV | |
|---|---|---|
Market Cap | $351.28B | $9.16B |
Volume | 7,969,665 | 5,030,325 |
Sector | Health | Consumer Cyclical |
52-Week High | $156.43 | $28.07 |
52-Week Low | $82.49 | $9.25 |
Typical Hold Time | 98 Days | 80 Days |
Enterprise Value | $398.04B | $11.09B |
Dividend Yield | 2.39% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Merck (MRK) trades at $145.6, up 1.97% today, with a bearish technical signal but strong fundamental performance. Recent earnings have consistently beaten estimates, and the company is expanding its oncology pipeline through the acquisition of Terns Pharmaceuticals. Revenue growth is steady, with 2025 revenue at $65.01B and net income of $18.25B, though 2026 projections show a significant drop in net income to $3.2B. The stock is supported by a high analyst buy consensus of 68.42% and a price target of $158.78.
The outlook for MRK is mixed; strong earnings beats and strategic acquisitions provide upside potential, but high valuation ratios and a projected earnings decline in 2026 pose risks. Investors should weigh the company's robust profitability and analyst support against execution risks and market volatility.
XPeng (XPEV) trades at $9.90, up 3.34% with a bearish technical signal despite recent delivery growth. The company shows improving fundamentals with revenue surging to $76.72B in 2025 and narrowing losses, though it remains unprofitable with negative margins. Recent news highlights expansion into robotics and global vehicle launches, while analyst consensus remains bullish with a $17.55 price target representing 77% upside potential.
XPeng presents a high-risk, high-reward opportunity with strong revenue growth and technological innovation offset by persistent profitability challenges. The stock's current discount to analyst targets offers potential upside, but investors face risks from competitive pressures, execution challenges in new business lines, and ongoing losses that could pressure the balance sheet.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Merck & Co., Inc.
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform is growing as a major contributor to overall sales. The company also has a substantial vaccine business, with treatments to prevent hepatitis B and pediatric diseases as well as HPV and shingles. Additionally, Merck sells animal health-related drugs. From a geographical perspective, just under half of the firm's sales are generated in the United States.
Read more on MRK →About Xpeng Inc - ADR
Founded in 2015, XPeng is a leading Chinese smart electric vehicle, or EV, company that designs, develops, manufactures and markets EVs in China. Its products primarily target the growing base of technology-savvy middle-class consumers in the midrange to high-end segment in China's passenger vehicle market. The company sold over 98,000 EVs in 2021, accounting for about 3% of China's passenger new energy vehicle market. It is also a leader in autonomous driving technology.
Read more on XPEV →
